Functional Viability Profiles of Breast Cancer
- 1 August 2011
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 1 (3), 260-273
- https://doi.org/10.1158/2159-8290.cd-11-0107
Abstract
The design of targeted therapeutic strategies for cancer has largely been driven by the identification of tumor-specific genetic changes. However, the large number of genetic alterations present in tumor cells means that it is difficult to discriminate between genes that are critical for maintaining the disease state and those that are merely coincidental. Even when critical genes can be identified, directly targeting these is often challenging, meaning that alternative strategies such as exploiting synthetic lethality may be beneficial. To address these issues, we have carried out a functional genetic screen in >30 commonly used models of breast cancer to identify genes critical to the growth of specific breast cancer subtypes. In particular, we describe potential new therapeutic targets for PTEN-mutated cancers and for estrogen receptor–positive breast cancers. We also show that large-scale functional profiling allows the classification of breast cancers into subgroups distinct from established subtypes. Significance: Despite the wealth of molecular profiling data that describe breast tumors and breast tumor cell models, our understanding of the fundamental genetic dependencies in this disease is relatively poor. Using high-throughput RNA interference screening of a series of pharmacologically tractable genes, we have generated comprehensive functional viability profiles for a wide panel of commonly used breast tumor cell models. Analysis of these profiles identifies a series of novel genetic dependencies, including that of PTEN-null breast tumor cells upon mitotic checkpoint kinases, and provides a framework upon which additional dependencies and candidate therapeutic targets may be identified. Cancer Discovery; 1(3); 260–73. © 2011 AACR. Read the Commentary on this article by Beijersbergen and Bernards, p. 205 This article is highlighted in the In This Issue feature, p. 189Other Versions
This publication has 42 references indexed in Scilit:
- Genetic Interactions in Cancer Progression and TreatmentCell, 2011
- Sustained Mps1 activity is required in mitosis to recruit O-Mad2 to the Mad1–C-Mad2 core complexThe Journal of cell biology, 2010
- 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancersNature Structural & Molecular Biology, 2010
- International network of cancer genome projectsNature, 2010
- A comprehensive catalogue of somatic mutations from a human cancer genomeNature, 2009
- Differential Enhancement of Breast Cancer Cell Motility and Metastasis by Helical and Kinase Domain Mutations of Class IA Phosphoinositide 3-KinaseCancer Research, 2009
- Synthetic lethal targeting of PTEN mutant cells with PARP inhibitorsEMBO Molecular Medicine, 2009
- Integrated Functional, Gene Expression and Genomic Analysis for the Identification of Cancer TargetsPLOS ONE, 2009
- Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activityProceedings of the National Academy of Sciences of the United States of America, 2007
- A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancersNature Genetics, 2006